Patient P-01503
Synthetic patientNBL-101 · Day 111 · 25–34 · F · baseline S15Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
51%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S15
- Day 17 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 34 ME-01 recommended — Monitoring Escalation ME-01
- Day 35 Patient accepted — Started ME-01 in the companion
- Day 38 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 17.
Primary contributors, last 14 days
- GI instability+25
- Nutritional resilience-13
- Inflammatory activity+5
- Treatment adherence+3
- Toxicity+3
What helped?
- Monitoring Escalation ME-01Day 34Result: deterioration detected before clinical escalation
LIFE OS recommendation
Clinician Review CR-01
72%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion31/100
improving · -3.6 vs previous 14 d
Toxicity
Blood24.8/100
worsening · +10.3 vs previous 14 d
Sleep quality
Wearable43.8/100
improving · +2.9 vs previous 14 d
Energy level
Daily log4.8/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log4.4/10
worsening · +0.3 vs previous 14 d
Steps
Wearable9,965
stable · +363 vs previous 14 d
Adherence
Companion96.2 %
stable · +0.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 77 from the failing basin, 15 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- HY-01 Hydration Protocolonly 38% improved among 8 similar
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Simple carbohydrates-1.6no signal · 35%
- Insoluble fibre+1.2no signal · 28%
- Dietary fat load-0.7no signal · 16%
- Histamine load+0.5no signal · 15%
- Spicy / capsaicin+0.5no signal · 15%
- Alcohol-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑25
- DNAIL6 -174 variant raises baseline inflammatory tone
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.4 · butyrate capacity 60/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 44 ms
- Sleep
- 6.7 h
- Steps
- 9,730
- Resting HR
- 65 bpm
Daily log: GI score 31, nutritional resilience 56, adherence 96.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01329 | 44% | S08 | BR-03 | improved | 79 |
| P-01479 | 42% | S15 | DT-01 | improved | 84 |
| P-01798 | 40% | S08 | NP-02 | improved | 78 |
| P-01625 | 39% | S06 | SC-12 | improved | 83 |
| P-01855 | 38% | S04 | DT-01 | improved | 73 |
| P-01495 | 37% | S07 | BR-03 | improved | 85 |
| P-01654 | 37% | S08 | CR-01 | improved | 85 |
| P-01671 | 37% | S04 | SC-12 | improved | 90 |
| P-01796 | 37% | S09 | SC-12 | improved | 86 |
| P-01439 | 36% | S18 | ME-01 | improved | 79 |
| P-01467 | 33% | S09 | HY-01 | improved | 79 |
| P-01791 | 33% | S06 | ME-01 | improved | 79 |